Growth and puberty after treatment for acute lymphoblastic leukemia

Detalhes bibliográficos
Autor(a) principal: Alves,Claudia Helena Bastos da Silva
Data de Publicação: 2004
Outros Autores: Kuperman,Hilton, Dichtchekenian,Vaê, Damiani,Durval, Della Manna,Thais, Cristófani,Lilian Maria, Odone Filho,Vicente, Setian,Nuvarte
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Hospital das Clínicas
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000200004
Resumo: Over the last 20 years, after combining treatment of chemotherapy and radiotherapy, there has been an improvement in the survival rate of acute lymphoblastic leukemia patients, with a current cure rate of around 70%. Children with the disease have been enrolled into international treatment protocols designed to improve survival and minimize the serious irreversible late effects. Our oncology unit uses the international protocol: GBTLI LLA-85 and 90, with the drugs methotrexate, cytosine, arabinoside, dexamethasone, and radiotherapy. However, these treatments can cause gonadal damage and growth impairment. PATIENTS AND METHOD: The authors analyzed 20 children off therapy in order to determine the role of the various doses of radiotherapy regarding endocrinological alterations. They were divided into 3 groups according to central nervous system prophylaxis: Group A underwent chemotherapy, group B underwent chemotherapy plus radiotherapy (18 Gy), and group C underwent chemotherapy plus radiotherapy (24 Gy). Serum concentrations of LH, FSH, GH, and testosterone were determined. Imaging studies included bone age, pelvic ultrasound and scrotum, and skull magnetic resonance imaging. RESULTS: Nine of the patients who received radiotherapy had decreased pituitary volume. There was a significant difference in the response to GH and loss of predicted final stature (Bayley-Pinneau) between the 2 irradiated groups and the group that was not irradiated, but there was no difference regarding the radiation doses used (18 or 24 Gy). The final predicted height (Bayley-Pinneau) was significantly less (P = 0.0071) in both groups treated with radiotherapy. Two girls had precocious puberty, and 1 boy with delayed puberty presented calcification of the epididymis. CONCLUSION: Radiotherapy was been responsible for late side effects, especially related to growth and puberty.
id USP-57_9f4fc7b81b72c671d45e2fc74e5e01f1
oai_identifier_str oai:scielo:S0041-87812004000200004
network_acronym_str USP-57
network_name_str Revista do Hospital das Clínicas
repository_id_str
spelling Growth and puberty after treatment for acute lymphoblastic leukemiaEndocrine dysfunction in lymphoblastic leukemiaGrowth and acute leukemiaPuberty in lymphoblastic leukemiaOver the last 20 years, after combining treatment of chemotherapy and radiotherapy, there has been an improvement in the survival rate of acute lymphoblastic leukemia patients, with a current cure rate of around 70%. Children with the disease have been enrolled into international treatment protocols designed to improve survival and minimize the serious irreversible late effects. Our oncology unit uses the international protocol: GBTLI LLA-85 and 90, with the drugs methotrexate, cytosine, arabinoside, dexamethasone, and radiotherapy. However, these treatments can cause gonadal damage and growth impairment. PATIENTS AND METHOD: The authors analyzed 20 children off therapy in order to determine the role of the various doses of radiotherapy regarding endocrinological alterations. They were divided into 3 groups according to central nervous system prophylaxis: Group A underwent chemotherapy, group B underwent chemotherapy plus radiotherapy (18 Gy), and group C underwent chemotherapy plus radiotherapy (24 Gy). Serum concentrations of LH, FSH, GH, and testosterone were determined. Imaging studies included bone age, pelvic ultrasound and scrotum, and skull magnetic resonance imaging. RESULTS: Nine of the patients who received radiotherapy had decreased pituitary volume. There was a significant difference in the response to GH and loss of predicted final stature (Bayley-Pinneau) between the 2 irradiated groups and the group that was not irradiated, but there was no difference regarding the radiation doses used (18 or 24 Gy). The final predicted height (Bayley-Pinneau) was significantly less (P = 0.0071) in both groups treated with radiotherapy. Two girls had precocious puberty, and 1 boy with delayed puberty presented calcification of the epididymis. CONCLUSION: Radiotherapy was been responsible for late side effects, especially related to growth and puberty.Faculdade de Medicina / Universidade de São Paulo - FM/USP2004-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000200004Revista do Hospital das Clínicas v.59 n.2 2004reponame:Revista do Hospital das Clínicasinstname:Universidade de São Paulo (USP)instacron:USP10.1590/S0041-87812004000200004info:eu-repo/semantics/openAccessAlves,Claudia Helena Bastos da SilvaKuperman,HiltonDichtchekenian,VaêDamiani,DurvalDella Manna,ThaisCristófani,Lilian MariaOdone Filho,VicenteSetian,Nuvarteeng2004-04-26T00:00:00Zoai:scielo:S0041-87812004000200004Revistahttp://www.scielo.br/rhcPUBhttps://old.scielo.br/oai/scielo-oai.php||revista.hc@hcnet.usp.br1678-99030041-8781opendoar:2004-04-26T00:00Revista do Hospital das Clínicas - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Growth and puberty after treatment for acute lymphoblastic leukemia
title Growth and puberty after treatment for acute lymphoblastic leukemia
spellingShingle Growth and puberty after treatment for acute lymphoblastic leukemia
Alves,Claudia Helena Bastos da Silva
Endocrine dysfunction in lymphoblastic leukemia
Growth and acute leukemia
Puberty in lymphoblastic leukemia
title_short Growth and puberty after treatment for acute lymphoblastic leukemia
title_full Growth and puberty after treatment for acute lymphoblastic leukemia
title_fullStr Growth and puberty after treatment for acute lymphoblastic leukemia
title_full_unstemmed Growth and puberty after treatment for acute lymphoblastic leukemia
title_sort Growth and puberty after treatment for acute lymphoblastic leukemia
author Alves,Claudia Helena Bastos da Silva
author_facet Alves,Claudia Helena Bastos da Silva
Kuperman,Hilton
Dichtchekenian,Vaê
Damiani,Durval
Della Manna,Thais
Cristófani,Lilian Maria
Odone Filho,Vicente
Setian,Nuvarte
author_role author
author2 Kuperman,Hilton
Dichtchekenian,Vaê
Damiani,Durval
Della Manna,Thais
Cristófani,Lilian Maria
Odone Filho,Vicente
Setian,Nuvarte
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Alves,Claudia Helena Bastos da Silva
Kuperman,Hilton
Dichtchekenian,Vaê
Damiani,Durval
Della Manna,Thais
Cristófani,Lilian Maria
Odone Filho,Vicente
Setian,Nuvarte
dc.subject.por.fl_str_mv Endocrine dysfunction in lymphoblastic leukemia
Growth and acute leukemia
Puberty in lymphoblastic leukemia
topic Endocrine dysfunction in lymphoblastic leukemia
Growth and acute leukemia
Puberty in lymphoblastic leukemia
description Over the last 20 years, after combining treatment of chemotherapy and radiotherapy, there has been an improvement in the survival rate of acute lymphoblastic leukemia patients, with a current cure rate of around 70%. Children with the disease have been enrolled into international treatment protocols designed to improve survival and minimize the serious irreversible late effects. Our oncology unit uses the international protocol: GBTLI LLA-85 and 90, with the drugs methotrexate, cytosine, arabinoside, dexamethasone, and radiotherapy. However, these treatments can cause gonadal damage and growth impairment. PATIENTS AND METHOD: The authors analyzed 20 children off therapy in order to determine the role of the various doses of radiotherapy regarding endocrinological alterations. They were divided into 3 groups according to central nervous system prophylaxis: Group A underwent chemotherapy, group B underwent chemotherapy plus radiotherapy (18 Gy), and group C underwent chemotherapy plus radiotherapy (24 Gy). Serum concentrations of LH, FSH, GH, and testosterone were determined. Imaging studies included bone age, pelvic ultrasound and scrotum, and skull magnetic resonance imaging. RESULTS: Nine of the patients who received radiotherapy had decreased pituitary volume. There was a significant difference in the response to GH and loss of predicted final stature (Bayley-Pinneau) between the 2 irradiated groups and the group that was not irradiated, but there was no difference regarding the radiation doses used (18 or 24 Gy). The final predicted height (Bayley-Pinneau) was significantly less (P = 0.0071) in both groups treated with radiotherapy. Two girls had precocious puberty, and 1 boy with delayed puberty presented calcification of the epididymis. CONCLUSION: Radiotherapy was been responsible for late side effects, especially related to growth and puberty.
publishDate 2004
dc.date.none.fl_str_mv 2004-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000200004
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000200004
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0041-87812004000200004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
dc.source.none.fl_str_mv Revista do Hospital das Clínicas v.59 n.2 2004
reponame:Revista do Hospital das Clínicas
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista do Hospital das Clínicas
collection Revista do Hospital das Clínicas
repository.name.fl_str_mv Revista do Hospital das Clínicas - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||revista.hc@hcnet.usp.br
_version_ 1754820894777147392